Author:
Majidova Nargiz,Sarı Murat,Kahvecioglu Fatma Akdag,Ozcan Erkan,Akdag Mutıianur Ozkorkmaz,Dogan Akif,Yıldırım Sedat,Sonusen Sermin Dinc,Yunusov Emil,Yasar Alper,Celebi Abdussamet,Sever Nadiye,Kocaaslan Erkam,Erel Pınar,Agyol Yesım,Guren Alı Kaan,Arıkan Rukıye,Isık Selver,Balvan Ozlem,Geredelı Caglayan,Uygun Kazım,Hacibekiroglu Ilhan,Kostek Osman,Bayoglu Ibrahım Vedat
Abstract
<b><i>Introduction:</i></b> Nasopharyngeal carcinoma (NPC) accounts for 0.01% of all carcinomas, and 70% of patients have locally advanced disease with a poor prognosis. The mainstay therapy is chemoradiotherapy (CRT), and concurrent administration of platinum-based agents and irradiation provides high local control rates. However, induction (neoadjuvant) chemotherapy (ICT) prior to CRT is recommended for large tumors with a high tumor burden at the category 1 level. For ICT, platinum-based doublet or triplet combination regimens are recommended. Selected patients with a high tumor burden at the time of diagnosis who did not receive ICT before CRT were given adjuvant (consolidation) therapy after CRT. This multicenter study aimed to share our experience in treatment of NPC and evaluate the factors associated with survival. <b><i>Methods:</i></b> The study included patients diagnosed with NPC who were followed and treated between 2008 and 2022. Hundred and forty-two patients from 6 centers were evaluated. The factors associated with disease-free survival (DFS) and overall survival (OS) were evaluated. <b><i>Results:</i></b> The median age of our patients was 51 years (IQR: 16–81 years), and the male:female ratio was 2.5:1. A majority of patients (71%) had stage 3–4 disease. They had locally advanced disease, and 48 patients (34%) received ICT. Twenty patients (14%) received adjuvant therapy. The median follow-up was 41 months (range, 2.7–175.1 months). The median DFS in NPC was 92.6 months (range, 71.9–113.3 months), with a 40th month DFS of 70.9%. The median OS was 113 months (range, 91–135 months), with a 40th month OS of 84.7%. Median DFS was 95.3 months (range, 64.2–126.4 months) in patients who received ICT before CRT, which was longer than in the CRT-only group (<i>p</i> = 0.6). DFS at the 40th month was 75.1% in patients treated with ICT compared to 65.1% in the CRT-only group. Median OS was 117 months (range, 92–142 months) in patients receiving ICT, which was longer than in the CRT-only group (<i>p</i> = 0.4). OS at the 40th month was 86.7% in patients receiving ICT but 83.6% in the CRT-only group. <b><i>Conclusions:</i></b> Both the objective response rate and survival were longer in patients who radiologically responded to CRT following ICT. Nonresponse to ICT is a negative predictive indicator. The role of ICT in locally advanced NPC is increasing.